Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study
Arthritis & Rheumatology2020Vol. 73(3), pp. 498–503
Citations Over TimeTop 10% of 2020 papers
Alice Canzian, Nils Venhoff, Maria Letizia Urban, Silvia Sartorelli, Anne‐Marie Ruppert, Matthieu Groh, N. Girszyn, Camille Taillé, F. Maurier, Vincent Cottin, Claire de Moreuil, Vincent Germain, Maxime Samson, M. Jachiet, Laure Denis, V. Rieu, P. Smets, G. Pugnet, Alban Deroux, Cécile‐Audrey Durel, Achille Aouba, P. Cathébras, C. Deligny, Stanislas Faguer, H. Gil, Bertrand Godeau, François Lifermann, S. Phin-Huynh, M. Ruivard, Philippe Bonniaud, Xavier Puéchal, Jean‐Emmanuel Kahn, Jens Thiel, Lorenzo Dagna, Loı̈c Guillevin, Augusto Vaglio, Giacomo Emmi, Benjamin Terrier, for the French Vasculitis Study Group and the European EGPA Study Group
Abstract
These results suggest that RTX could be effective in treating relapses of EGPA vasculitis. MEPO is highly effective with a good safety profile in patients with GC-dependent asthma. Our data suggest that 100 mg MEPO monthly could be an acceptable dosage for first-line therapy in selected instances of EGPA, recognizing, however, that this has not been compared to the validated dosage of 300 mg monthly.
Related Papers
- → Update on eosinophilic granulomatosis with polyangiitis(2019)243 cited
- → Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab(2020)18 cited
- → Mepolizumab for eosinophilic granulomatosis with polyangiitis(2017)16 cited
- → Mepolizumab -- therapeutic strategy for a paediatric patient with eosinophilic granulomatosis with polyangiitis(2022)1 cited
- → Treatment of ANCA-Associated Vasculitides(2019)1 cited